发明授权
EP2509955B1 PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL
有权
吡唑衍生物作为钙释放活化钙通道的调节剂
- 专利标题： PYRAZOLE DERIVATIVES AS MODULATORS OF CALCIUM RELEASE-ACTIVATED CALCIUM CHANNEL
- 专利标题（中）： 吡唑衍生物作为钙释放活化钙通道的调节剂
-
申请号： EP10779334.1申请日： 2010-10-07
-
公开(公告)号： EP2509955B1公开(公告)日： 2018-04-25
- 发明人: MUTHUPPALANIAPPAN, Peyyappan , VISWANADHA, Srikant , MERIKAPUDI, Gayatri, Swaroop , VAKKALANKA, Swaroop, Kumar, V.S.
- 申请人： Rhizen Pharmaceuticals S.A.
- 申请人地址： Fritz Courvoisier 40 2300 La Chaux de Fonds CH
- 专利权人： Rhizen Pharmaceuticals S.A.
- 当前专利权人： Rhizen Pharmaceuticals S.A.
- 当前专利权人地址： Fritz Courvoisier 40 2300 La Chaux de Fonds CH
- 代理机构： Pons
- 优先权： IN2439CH2009 20091008; IN2636CH2009 20091030; IN158CH2010 20100125; IN1513CH2010 20100602; IN1514CH2010 20100602; US265540P 20091201
- 国际公布： WO2011042797 20110414
- 主分类号： C07D231/12
- IPC分类号： C07D231/12 ; C07D401/04 ; C07D401/12 ; C07D401/14 ; C07D403/04 ; C07D403/12 ; C07D403/14 ; C07D413/12 ; C07D413/14 ; C07D417/12 ; C07D417/14 ; A61P35/00 ; A61K31/415 ; A61K31/4155
摘要：
Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.
公开/授权文献
信息查询
